Advertisement

Topics

AstraZeneca announces OS data from breast cancer treatment Lynparza

10:10 EDT 18 Apr 2018 | Net Resources International

AstraZeneca and Merck have announced overall survival (OS) data from Phase III trial OlympiAD examining Lynparza (olaparib) as a treatment...
Read More...

The post AstraZeneca announces OS data from breast cancer treatment Lynparza appeared first on Drug Development Technology.

Original Article: AstraZeneca announces OS data from breast cancer treatment Lynparza

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca announces OS data from breast cancer treatment Lynparza"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...